Equities researchers at StockNews.com initiated coverage on shares of Diffusion Pharmaceuticals (NASDAQ:DFFN – Get Rating) in a research note issued to investors on Thursday. The brokerage set a "hold" rating on the stock.
Separately, HC Wainwright upgraded shares of Diffusion Pharmaceuticals from a "neutral" rating to a "buy" rating and set a $9.50 price objective for the company in a research report on Tuesday, August 16th.
Get Diffusion Pharmaceuticals alerts:Diffusion Pharmaceuticals Stock Up 3.3 %
Shares of Diffusion Pharmaceuticals stock opened at $6.30 on Thursday. Diffusion Pharmaceuticals has a fifty-two week low of $5.10 and a fifty-two week high of $28.25. The business has a 50-day moving average price of $7.01 and a 200 day moving average price of $11.48. The firm has a market cap of $12.85 million, a P/E ratio of -0.51 and a beta of 1.53.
Diffusion Pharmaceuticals (NASDAQ:DFFN – Get Rating) last released its quarterly earnings results on Thursday, August 11th. The company reported ($2.06) EPS for the quarter, missing analysts' consensus estimates of ($1.77) by ($0.29). As a group, equities research analysts anticipate that Diffusion Pharmaceuticals will post -8.43 earnings per share for the current year.Institutional Inflows and Outflows
Institutional investors and hedge funds have recently modified their holdings of the business. Trexquant Investment LP acquired a new position in shares of Diffusion Pharmaceuticals in the 2nd quarter valued at about $71,000. JPMorgan Chase & Co. purchased a new stake in shares of Diffusion Pharmaceuticals during the first quarter worth $106,000. Finally, Renaissance Technologies LLC lifted its stake in shares of Diffusion Pharmaceuticals by 8.3% in the 1st quarter. Renaissance Technologies LLC now owns 1,324,202 shares of the company's stock valued at $331,000 after purchasing an additional 101,100 shares during the last quarter. Hedge funds and other institutional investors own 10.25% of the company's stock.
Diffusion Pharmaceuticals Company Profile
(Get Rating)
Diffusion Pharmaceuticals Inc, a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. Diffusion Pharmaceuticals Inc was founded in 2001 and is based in Charlottesville, Virginia.
Featured Stories
- Get a free copy of the StockNews.com research report on Diffusion Pharmaceuticals (DFFN)
- Is This Medical Gear Maker Ready To Continue Its Rally?
- The Five (5) Hottest Stocks To Watch Ahead Of Q3 Earnings
- Has Take-Two Interactive Devolved into a One-Trick Pony?
- Four Cheap Stocks With Interesting Insider Activity
- Is Lyft Going To Make It As Acquisition Rumors Swirl?
Receive News & Ratings for Diffusion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diffusion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.